4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
A novel cyclized histatin-based peptide DB2-121 that is a potent new antifungal agent active against the clinically important Candida albicans and a number of other organisms. More
A fermented soymilk extract, MS-20, is in Phase II (US FDA and Taiwan DOH) and Phase III (Taiwan DOH) clinical trials for the treatment of cachexia in liver cancer patients and for reducing neutropenic fever in cancer patients undergoing chemotherapy More
CA-88 is a botanically derived auxiliary treatment that has been shown to exhibit healthful benefits for patients undergoing cancer chemotherapy and radiotherapy. More
Exclusive license for use of gabapentin in the above indications in EU, Canada, Australia, New Zealand. US Phase 3 trials of MR-gabapentin for menopause by PharmaNova’s US licensee (Depomed, Inc) will complete in 3Q 2009; Co-promotion in US is possible. More
A pharmacogenetic method to identify candidates who are most likely to benefit from treatment with statins to reduce cancer risk, and consequently minimizing any unnecessary cost and side effects in individuals who do not benefit. More
These compounds might avoid the well-documented side-effects observed in clinical trials of "classical" MDR1 inhibitors and may serve as leads for development of novel anti-cancer agents to treat resistant disease. More
All rights reserved. Terms and Conditions | Contact us
